CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 119 enrolled
Drug / intervention
ferumoxytol +2 moredrug
Likely dose
ferumoxytol 1.0 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00707876
NCT00707876Phase 2Completed
CompareCT.gov

Phase II, Open Label, Randomized, Multicenter Trial Comparing Noncontrast MRA vs. Ferumoxytol Vascular Enhanced MRI for Detection of Stenosis or Occlusion of the Aortoiliac and Superficial Femoral Arteries in PAD Subjects Scheduled for DSA

AMAG Pharmaceuticals, Inc.·interventional·Posted Jul 1, 2008·Updated Apr 16, 2026

In Brief

A Phase 2 clinical trial evaluating ferumoxytol for Peripheral Arterial Disease (PAD). Completed, enrolled 119 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the difference between two magnetic resonance imaging (MRI) techniques for visualizing arteries. The study hypothesizes that one method that relies upon imaging flowing blood in the pelvic and leg arteries will not be as accurate or efficient as injecting a safe imaging agent to change the appearance of the blood on the MRI. Both methods will be compared with Digital Subtraction Angiography (DSA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Disease (PAD)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 1, 2008
Enrollment StartSep 1, 2008
Primary CompletionJul 2, 2010
Study CompletionAug 15, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.0 years ago

Interventions

ferumoxytoldrug

1.0 mg/kg IV ferumoxytol

ferumoxytoldrug

2.5 mg/kg IV ferumoxytol

ferumoxytoldrug

4.0 mg/kg IV ferumoxytol